

Caprelsa (vandetanib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Caprelsa (vandetanib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Caprelsa (vandetanib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease;

OR

- II. Individual has a diagnosis of Thyroid carcinoma, including papillary, follicular, and Hürthle Cell carcinomas (NCCN 2A); **AND**
- III. Other systemic therapies or clinical trials are unavailable or not appropriate for treatment of progressive and/or symptomatic iodine-refractory disease (NCCN 2A).

Requests for Caprelsa (vandetanib) may not be approved for the following:

- I. Individuals with congenital long QT syndrome.

Note:

Caprelsa (vandetanib) has black box warnings for QT prolongation, torsades de pointes, and sudden death. Caprelsa should not be used in individuals with hypocalcemia, hypokalemia, hypomagnesemia, or long QT syndrome. Hypocalcemia, hypokalemia and/or hypomagnesemia should be corrected prior to administration. Electrolytes should be monitored periodically during therapy. Drugs known to prolong the QT interval should be avoided. Caprelsa is only available through a restricted distribution REMS program.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2021. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 7, 2021.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2021 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on June 7, 2021.
 - a. Thyroid Carcinoma. V1.2021. Revised April 9, 2021.
 - b. Non-small cell lung cancer. V4.2021. Revised March 3, 2021.